{"id":4151,"date":"2026-02-03T17:30:42","date_gmt":"2026-02-03T17:30:42","guid":{"rendered":"https:\/\/5primesciences.com\/communique-de-presse-dexoligo\/"},"modified":"2026-02-03T17:33:48","modified_gmt":"2026-02-03T17:33:48","slug":"communique-de-presse-dexoligo","status":"publish","type":"page","link":"https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/","title":{"rendered":"Communiqu\u00e9 de presse Dexoligo"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

5Prime Sciences et Dexoligo Therapeutics annoncent leur collaboration en mati\u00e8re de d\u00e9couverte de cibles pour des th\u00e9rapies \u00e0 base de GalNAc-siRNA dirig\u00e9es vers le foie.<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Montr\u00e9al, Canada [2026\/FEB\/03 09:00 EDT] – 5Prime Sciences Inc, une soci\u00e9t\u00e9 de d\u00e9couverte de cibles bas\u00e9e sur la g\u00e9nomique, a annonc\u00e9 aujourd’hui une collaboration de recherche strat\u00e9gique avec Dexcel Pharma Technologies Ltd, par l’interm\u00e9diaire de Dexoligo Therapeutics. par l’interm\u00e9diaire de Dexoligo Therapeutics, afin de d\u00e9couvrir des cibles exprim\u00e9es dans le foie et soutenues g\u00e9n\u00e9tiquement, en vue de les d\u00e9velopper \u00e0 l’aide de th\u00e9rapies GalNAc-siRNA. <\/span><\/p>

5Prime a \u00e9t\u00e9 fond\u00e9e pour acc\u00e9l\u00e9rer le d\u00e9veloppement de m\u00e9dicaments en identifiant des cibles m\u00e9dicamenteuses causales et des biomarqueurs, ainsi que pour identifier des patients en vue de l’enrichissement des essais cliniques. Dans le cadre de cette collaboration, 5Prime utilisera les donn\u00e9es de la g\u00e9n\u00e9tique humaine et de la multiomique pour identifier les cibles exprim\u00e9es dans le foie qui ont un lien de causalit\u00e9 clair avec la maladie et une justification biologique solide. Dexoligo Therapeutics dirigera le d\u00e9veloppement en aval et la commercialisation des programmes s\u00e9lectionn\u00e9s. <\/span><\/p>

\u00ab\u00a0Chez 5Prime, nous nous engageons \u00e0 utiliser la biologie humaine causale pour guider de meilleures d\u00e9cisions dans la d\u00e9couverte de m\u00e9dicaments\u00a0\u00bb, a d\u00e9clar\u00e9 Brent Richards, PDG de 5Prime. \u00ab\u00a0Cette collaboration nous permet d’appliquer cette approche aux th\u00e9rapies ARN dirig\u00e9es contre le foie, en collaboration avec un partenaire poss\u00e9dant une expertise en mati\u00e8re de d\u00e9veloppement\u00a0\u00bb, a d\u00e9clar\u00e9 Brent Richards. <\/span>Brent Richards, PDG de 5Prime<\/b>.<\/span><\/p>

\u00ab\u00a0Pour Dexoligo, ce partenariat renforce notre portefeuille de produits en nous donnant acc\u00e8s \u00e0 des cibles qui sont bien \u00e9tay\u00e9es par des donn\u00e9es causales chez l’homme \u00ab\u00a0, a d\u00e9clar\u00e9 Shay Sela, responsable de Dexoligo Therapeutics. <\/span>Shay Sela, responsable de Dexoligo Therapeutics.<\/b> \u00ab\u00a0Il nous aide \u00e0 concentrer nos efforts sur des programmes qui ont plus de chances d’\u00eatre transform\u00e9s en th\u00e9rapies significatives.<\/span><\/p>

Les conditions financi\u00e8res comprennent des frais de service de recherche et la possibilit\u00e9 de paiements d’\u00e9tape et de redevances en aval.<\/span><\/p>

\u00c0 propos de Five Prime Sciences<\/b><\/p>

Five Prime Sciences est une soci\u00e9t\u00e9 de recherche et de d\u00e9veloppement multiomique ax\u00e9e sur la g\u00e9nomique, qui se consacre \u00e0 l’identification et \u00e0 la validation de cibles g\u00e9n\u00e9tiques pour le d\u00e9veloppement de th\u00e9rapies.<\/span><\/p>

\u00c0 propos de Dexoligo Therapeutics<\/b><\/p>

Dexoligo Therapeutics a \u00e9t\u00e9 cr\u00e9\u00e9 en 2021 par <\/span>Dexcel Pharma<\/span><\/a> dans le but d’\u00e9tablir un projet th\u00e9rapeutique ARN innovant et \u00e0 fort impact. <\/span> <\/p>

Cliquez ici pour un fichier pdf<\/a> du communiqu\u00e9 de presse.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

5Prime Sciences et Dexoligo Therapeutics annoncent leur collaboration en mati\u00e8re de d\u00e9couverte de cibles pour des th\u00e9rapies \u00e0 base de GalNAc-siRNA dirig\u00e9es vers le foie. Montr\u00e9al, Canada [2026\/FEB\/03 09:00 EDT] – 5Prime Sciences Inc, une soci\u00e9t\u00e9 de d\u00e9couverte de cibles bas\u00e9e sur la g\u00e9nomique, a annonc\u00e9 aujourd’hui une collaboration de recherche strat\u00e9gique avec Dexcel Pharma … Lire la suite<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4151","page","type-page","status-publish"],"yoast_head":"\nCommuniqu\u00e9 de presse Dexoligo - 5PrimeSciences<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9 de presse Dexoligo - 5PrimeSciences\" \/>\n<meta property=\"og:description\" content=\"5Prime Sciences et Dexoligo Therapeutics annoncent leur collaboration en mati\u00e8re de d\u00e9couverte de cibles pour des th\u00e9rapies \u00e0 base de GalNAc-siRNA dirig\u00e9es vers le foie. Montr\u00e9al, Canada [2026\/FEB\/03 09:00 EDT] – 5Prime Sciences Inc, une soci\u00e9t\u00e9 de d\u00e9couverte de cibles bas\u00e9e sur la g\u00e9nomique, a annonc\u00e9 aujourd’hui une collaboration de recherche strat\u00e9gique avec Dexcel Pharma ... Lire la suite\" \/>\n<meta property=\"og:url\" content=\"https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/\" \/>\n<meta property=\"og:site_name\" content=\"5PrimeSciences\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T17:33:48+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/communique-de-presse-dexoligo\\\/\",\"url\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/communique-de-presse-dexoligo\\\/\",\"name\":\"Communiqu\u00e9 de presse Dexoligo - 5PrimeSciences\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-02-03T17:30:42+00:00\",\"dateModified\":\"2026-02-03T17:33:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/communique-de-presse-dexoligo\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/5primesciences.com\\\/fr\\\/communique-de-presse-dexoligo\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/communique-de-presse-dexoligo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9 de presse Dexoligo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/\",\"name\":\"5PrimeSciences\",\"description\":\"The best medicines start with the best targets. We use human genetics to accelerate drug development.\",\"publisher\":{\"@id\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/#organization\",\"name\":\"5PrimeSciences\",\"url\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/5primesciences.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/5primesciences.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/logo.png\",\"width\":377,\"height\":79,\"caption\":\"5PrimeSciences\"},\"image\":{\"@id\":\"https:\\\/\\\/5primesciences.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9 de presse Dexoligo - 5PrimeSciences","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9 de presse Dexoligo - 5PrimeSciences","og_description":"5Prime Sciences et Dexoligo Therapeutics annoncent leur collaboration en mati\u00e8re de d\u00e9couverte de cibles pour des th\u00e9rapies \u00e0 base de GalNAc-siRNA dirig\u00e9es vers le foie. Montr\u00e9al, Canada [2026\/FEB\/03 09:00 EDT] – 5Prime Sciences Inc, une soci\u00e9t\u00e9 de d\u00e9couverte de cibles bas\u00e9e sur la g\u00e9nomique, a annonc\u00e9 aujourd’hui une collaboration de recherche strat\u00e9gique avec Dexcel Pharma ... Lire la suite","og_url":"https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/","og_site_name":"5PrimeSciences","article_modified_time":"2026-02-03T17:33:48+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/","url":"https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/","name":"Communiqu\u00e9 de presse Dexoligo - 5PrimeSciences","isPartOf":{"@id":"https:\/\/5primesciences.com\/fr\/#website"},"datePublished":"2026-02-03T17:30:42+00:00","dateModified":"2026-02-03T17:33:48+00:00","breadcrumb":{"@id":"https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/5primesciences.com\/fr\/communique-de-presse-dexoligo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/5primesciences.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9 de presse Dexoligo"}]},{"@type":"WebSite","@id":"https:\/\/5primesciences.com\/fr\/#website","url":"https:\/\/5primesciences.com\/fr\/","name":"5PrimeSciences","description":"The best medicines start with the best targets. We use human genetics to accelerate drug development.","publisher":{"@id":"https:\/\/5primesciences.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/5primesciences.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/5primesciences.com\/fr\/#organization","name":"5PrimeSciences","url":"https:\/\/5primesciences.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/5primesciences.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/5primesciences.com\/wp-content\/uploads\/2021\/10\/logo.png","contentUrl":"https:\/\/5primesciences.com\/wp-content\/uploads\/2021\/10\/logo.png","width":377,"height":79,"caption":"5PrimeSciences"},"image":{"@id":"https:\/\/5primesciences.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/5primesciences.com\/fr\/wp-json\/wp\/v2\/pages\/4151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/5primesciences.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/5primesciences.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/5primesciences.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/5primesciences.com\/fr\/wp-json\/wp\/v2\/comments?post=4151"}],"version-history":[{"count":3,"href":"https:\/\/5primesciences.com\/fr\/wp-json\/wp\/v2\/pages\/4151\/revisions"}],"predecessor-version":[{"id":4160,"href":"https:\/\/5primesciences.com\/fr\/wp-json\/wp\/v2\/pages\/4151\/revisions\/4160"}],"wp:attachment":[{"href":"https:\/\/5primesciences.com\/fr\/wp-json\/wp\/v2\/media?parent=4151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}